BioAdaptives® Inc. Announces XcellaraHeart™, a Cardiovascular Wellness Formula Built on Xcellara’s Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells
The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and cardiovascular repair-response biology The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and cardiovascular repair-response biology
The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and cardiovascular repair-response biology The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and cardiovascular repair-response biology
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.